Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|June 9, 2026 (Updated: June 9, 2026)

BioPharm Brief: RNAi, Obesity, and Diabetes Advances

This week's BioPharm Brief highlights City Therapeutics' efforts to advance its RNAi pipeline with a new financing round, positive Phase 3 data for survodutide in obesity and MASLD, and Lilly's oral GLP-1 Foundayo outperforming oral semaglutide in a landmark head-to-head type 2 diabetes trial.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Three notable developments are highlighting continued innovation across RNA interference, obesity, and metabolic disease therapies.

First, City Therapeutics announced a $99.5 million Series B financing to advance its next-generation RNAi platform and pipeline. The funding will support development of CITY-FXI, which recently entered a Phase 1 clinical trial for thromboembolic diseases, as well as CITY-RBP4, an investigational RNAi therapy for Stargardt disease that is expected to enter the clinic later this year. Company leaders said the financing will help accelerate multiple programs and further validate the potential of next-generation RNAi technologies.

In obesity and liver disease news, Boehringer Ingelheim and Zealand Pharma reported positive Phase 3 data for survodutide, a dual glucagon and GLP-1 receptor agonist. Across two studies, the investigational therapy significantly reduced visceral adipose tissue and liver fat content in adults with obesity and metabolic dysfunction-associated steatotic liver disease, or MASLD. Researchers noted that reductions in liver fat and visceral fat are considered important markers of cardiometabolic health and may support broader disease management beyond weight loss alone.

Finally, Eli Lilly reported detailed Phase 3 results for its oral GLP-1 receptor agonist Foundayo, also known as orforglipron. In the ACHIEVE-3 study, Foundayo outperformed oral semaglutide on measures of both A1C reduction and weight loss, marking the first head-to-head Phase 3 comparison of two oral GLP-1 therapies in type 2 diabetes. Lilly also reported positive findings from two additional Phase 3 trials and plans to submit Foundayo to the FDA for type 2 diabetes by the end of the second quarter.

That's all for today's BioPharm Brief. For further analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

  • City Therapeutics secured $99.5 million in Series B financing to advance its RNAi pipeline, including the Phase 1 CITY-FXI program and a Stargardt disease candidate expected to enter the clinic later this year.
  • Survodutide delivered significant reductions in visceral adipose tissue and liver fat in Phase 3 studies, reinforcing the potential of incretin-based therapies to address obesity and metabolic dysfunction-associated steatotic liver disease.
  • Lilly's oral GLP-1 Foundayo outperformed oral semaglutide in a landmark Phase 3 head-to-head trial, achieving greater reductions in both A1C and body weight and strengthening the case for oral GLP-1 therapies in type 2 diabetes treatment.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more